| Because TNF inhibitors increase the risk of tuberculosis reactivation, current guidelines recommend tuberculosis screening before starting any biologic drug, and chemoprophylaxis if a latent infection (LTBI) is diagnosed. |
| The risk of tuberculosis reactivation in patients with psoriasis and LTBI does not seem to increase with IL-17 or IL-23 inhibitors. |
| IL-17 or IL-23 inhibitors should be preferred over TNF antagonists in patients with LTBI considered at high risk for developing complications related to chemoprophylaxis, avoiding this preventive strategy. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.